Clinical Trials Logo

Clinical Trial Summary

The MENDEL-study will investigate whether the use of gene panel or whole genome sequencing (WGS) will:

1. improve the rate of diagnosis and through this compare the performance of the two diagnostic approaches (gene panel vs. WGS),

2. investigate whether use of said sequencing approaches early in the diagnostic process results in reduced health care spending, and

3. result in an improved quality of life for the patients and their parents.


Clinical Trial Description

Patients will be recruited from in- and outpatient clinics at the Otto Heubner Center, the Berlin Center for Rare Diseases, and the Institute for Medical Genetics and Human Genetics at Charité-Universitätsmedizin Berlin, Germany. Following informed consent, 5 ml EDTA blood will be obtained from the index case and 10 ml blood from each parent. Disease related phenotype information and the outcome of previous diagnostic tests and procedures will be recorded as part of Study visit #1.

[1] Study visit #1

1. A medical genetics physical will be performed. Detailed clinical symptoms (phenotype) will be recorded using Human Phenotype Ontology (HPO) terminology.

2. A detailed pedigree will be drawn.

3. Age of disease onset will be determined.

4. Results from previous diagnostic tests and procedures, as well as hospital stays, will be recorded.

5. The parents will be asked to complete a validated, standardized quality of life questionnaire adapted for for rare disease. The questionnaire is available online or in paper form.

[2] Study visit #2a (optional)

This study visit will only take place in the event that gene panel sequencing identifies a variant of uncertain significance, where additional information would be needed in order to determine its pathogenicity (e.g. confirmational biochemical testing, collection of additional information). Relevant research findings will be discussed and the nature and necessity of the additional testing will be explained.

[3] Study visit #2b (optional)

This study visit will only take place in the event that WGS identifies a variant of uncertain significance where additional information is needed in order to determine its pathogenicity > see Study visit #2a.

[4] Study visit #3 (results session)

Results will be returned in the context of a genetic counseling session.

[5] Study visit #4 (6 months after Study visit #3)

The parents will be asked to complete the validated, standardized quality of life questionnaire adapted for rare disease again. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02380729
Study type Observational
Source Charite University, Berlin, Germany
Contact
Status Completed
Phase N/A
Start date January 31, 2015
Completion date December 31, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT02657811 - Time-Lapse Incubation for Embryo Culture - Morphokinetics and Environmental Stability N/A
Completed NCT01279733 - Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis N/A
Completed NCT03984266 - The Pilot Study of High-throughput Sequencing in Neonatal Birth Defects
Recruiting NCT00001373 - Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Active, not recruiting NCT03211039 - Perinatal Precision Medicine N/A
Recruiting NCT02650622 - Genetic and Metabolic Disease in Children
Recruiting NCT02917460 - Rady Children's Institute Genomic Biorepository N/A
Terminated NCT02807961 - Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers Phase 1
Completed NCT02642653 - Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome Phase 4
Completed NCT06260319 - Decoding Developmental Disorders in Humams
Completed NCT02160938 - Prenatal Microarray Follow-Up Study
Completed NCT02512679 - Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Phase 2
Recruiting NCT06235580 - Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions
Enrolling by invitation NCT03385876 - Rapid Whole Genome Sequencing Study N/A
Recruiting NCT02717650 - The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis. N/A